TABLE 1.
Comparisons of the hazard rate of developing graft loss (death uncensored) by treatment arm.
| Outcome | Group A: TAC/SRL (N = 50) | Group B: TAC/MMF (N = 50) | Group C: CSA/SRL (N = 50) | Log rank test p‐value a |
|---|---|---|---|---|
| Graft loss (death uncensored) b | ||||
| During first 60 months | 15 (70.0% ± 6.5%) | 14 (71.7% ± 6.4%) | 10 (79.8% ± 5.7%) | 0.56 |
| During first 120 months | 26 (46.7% ± 7.2%) | 20 (58.7% ± 7.1%) | 17 (65.0% ± 6.9%) | 0.24 |
| During first 180 months | 29 (39.0% ± 7.3%) | 27 (42.4% ± 7.3%) | 28 (39.2% ± 7.4%) | 0.77 |
| During first 240 months | 34 (23.6% ± 7.0%) | 36 (17.8% ± 6.2%) | 34 (23.9% ± 6.7%) | 0.83 |
Note: Number of patients with the event (Kaplan–Meier [actuarial] [death uncensored] graft survival estimates at 60 120, 180, and 240 months post‐transplant ± SE), respectively.
Abbreviations: CSA, cyclosporine microemulsion; MMF, mycophenolate mofetil; SRL, sirolimus; TAC, tacrolimus.
The p values listed in this column represent the results of the log‐rank test (with 2 degrees of freedom) for any differences among the three treatment groups’ hazard rates of graft loss (death uncensored).
The risk set of patients (who were still alive with a functioning graft) at 60 months post‐transplant was 35, 34, and 39 in groups A, B, and C, respectively. The risk set of patients (who were still alive with a functioning graft) at 120 months post‐transplant was 19, 27, and 30 in groups A, B, and C, respectively. The risk set of patients (who were still alive with a functioning graft) at 180 months post‐transplant was 13, 17, and 16 in groups A, B, and C, respectively. Last, the risk set of patients (who were still alive with a functioning graft) at 240 months post‐transplant was 7, 5, and 8 in groups A, B, and C, respectively. Patients without graft loss who were also not in the risk set at a particular timepoint were lost to follow‐up.